Overview of Allegro

Property	Description
Active ingredient	Frovatriptan (as Frovatriptan succinate)
Form	Film-coated tablet (Oral administration)
Pharmacological class	Selective Serotonin Receptor Agonist (Triptan)
General purpose	Acute treatment for migraine attacks
Origin	Synthetic compound

Frovatriptan: What Type of Anti-Migraine Medicine is Allegro?

Allegro is the trade name for a highly targeted synthetic prescription medication containing the active ingredient Frovatriptan (INN). Frovatriptan is classified as a Triptan, belonging to the pharmacological class of selective serotonin receptor agonists. These agents are specifically designed to address the underlying neurovascular changes associated with acute migraine attacks.

Frovatriptan is recognized as a second-generation Triptan, distinguished by its unique pharmacokinetic profile. It possesses the longest terminal elimination half-life among the triptans, measuring approximately 26 hours. This prolonged activity is clinically supported for providing sustained relief and potentially reducing the rate of headache recurrence following successful acute treatment.

Composition and Form: What is Allegro Made Of?

The core chemical component of Allegro is Frovatriptan succinate, establishing it as a single-ingredient product. The medication is formulated exclusively for oral administration and is presented as a small, film-coated tablet. This standardized form of delivery is chemically distinct from other triptans that may be available in alternative dosage forms, offering patients a fixed and non-invasive method of treatment.

What is the General Purpose of Allegro?

The general therapeutic purpose of Allegro is the acute treatment of migraine attacks, meaning it is taken to interrupt the episode once it has started. Its function involves a dual action: selectively constricting certain dilated cranial blood vessels and inhibiting the release of key pro-inflammatory pain chemicals. This neurovascular mechanism is geared toward providing targeted relief from the severe, debilitating head pain of an ongoing migraine episode.

What side effects are possible with Allegro?

The official safety profile for Allegro (Frovatriptan) classifies potential adverse reactions based on regulatory frequency categories and the physiological system affected. Most effects reported in clinical studies were transient and described as mild to moderate in severity.

Common Adverse Reactions

Adverse reactions classified as common (occurring in up to 1 in 10 people) typically involve the nervous and gastrointestinal systems. These frequently documented effects include dizziness, nausea, dry mouth, fatigue, somnolence (sleepiness), and abnormal sensations such as paresthesia (pins and needles). Symptoms of chest discomfort, tightness, or pressure in the throat or neck are also commonly reported.

Serious Risks and Safety Restrictions

The regulatory prescribing information documents specific, clinically significant risks primarily involving the vascular system. These serious adverse reactions include events such as Myocardial Ischemia or Infarction, Coronary Vasospasm, and Cerebrovascular Events (e.g., stroke). The risk of Serotonin Syndrome is also listed, particularly with co-administration of other serotonergic medicines.

Allegro is contraindicated and must not be used in individuals with a history of Ischemic Heart Disease, uncontrolled Hypertension, Peripheral Vascular Disease, or specific migraine types like Hemiplegic or Basilar Migraine.

Population-Specific Safety Considerations

Safety and effectiveness have not been established for pediatric patients (under 18 years of age), and use is not recommended for older adults (65 years and over) due to a lack of sufficient clinical experience in this group. Additionally, the label identifies the potential for Medication Overuse Headache (MOH) if the medication is taken for ten or more days per month.

Overdose and Emergency Response

Overdose with Frovatriptan (Allegro) is officially managed as a medical emergency, with mandated procedures defined by regulatory documents. The official prescribing information notes that single doses significantly higher than the recommended amount have led to a greater incidence of adverse events in clinical studies.

Required Emergency Action

When an overdose is suspected, immediate medical attention must be sought. Emergency services should be contacted if the individual has severe clinical manifestations such as collapse, seizure, severe breathing difficulty, or loss of consciousness. The management strategy is symptomatic and supportive, as no specific antidote for Frovatriptan is documented in regulatory labeling.

Monitoring and Severe Outcomes

Due to the drug’s long terminal elimination half-life of approximately 26 hours, continuous patient monitoring is required for at least 48 hours or until all signs and symptoms have fully resolved. Overdose scenarios require rigorous monitoring for serious, life-threatening complications related to the drug class. These officially documented severe outcomes include:

Serotonin Syndrome
Life-threatening disturbances of cardiac rhythm
Cerebrovascular events (e.g., stroke, cerebral hemorrhage)

The official labeling also notes that the effect of hemodialysis or peritoneal dialysis on Frovatriptan concentration is unknown, which is a consideration for management.

Therapeutic Uses of Allegro

Allegro (Frovatriptan) is commonly used across conditions presenting with acute episodes of migraine in adults, relevant for both migraine with aura and migraine without aura.

the medication helps address the severe, pulsating head pain that characterizes the acute phase, supporting the easing of the overall symptom load. It is relevant for managing symptom clusters that may become intense or disruptive, such as nausea, vomiting, photophobia, and phonophobia. The clinical utility is often applied in scenarios where additional management of discomfort is required, and is considered relevant in situations involving recurrent or episodic manifestations like menstrual-related migraine (MRM).

“Frovatriptan provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability during difficult episodes.”

Quick Fact: Symptomatic Support for Recurrence

Allegro is relevant in contexts involving heightened systemic burden, offering sustained symptomatic benefit to patients. This supports patients during episodes of heightened discomfort by helping to ease the overall symptom load, and is relevant when symptoms become more disruptive during flare-ups.

Regulatory References

NIH DailyMed official drug label

Eligibility and Restrictions for Use

Allegro (Frovatriptan) is strictly indicated for use in adults, generally between the ages of 18 and 65, for the acute treatment of migraine attacks. The official eligibility profile focuses on excluding populations with specific cardiovascular risks and certain medical conditions.

Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated for patients with a history of ischemic heart disease, stroke, or uncontrolled hypertension. It must not be used by individuals with cardiac accessory conduction pathway disorders (like Wolff-Parkinson-White syndrome), peripheral vascular disease, or severe hepatic impairment. Use is also prohibited within 24 hours of taking another triptan or ergotamine-containing medication. Furthermore, Allegro is contraindicated for treating hemiplegic or basilar migraine.

Age-Related and Conditional Eligibility

Use is not recommended in the pediatric population (under 18 years) or in older adults (over 65 years) as safety and effectiveness have not been fully established in these groups. No dosage adjustment is required for patients with renal impairment or those with mild to moderate hepatic impairment. For pregnant women, use is generally not recommended unless clearly necessary. Breastfeeding women are advised to observe a 24-hour interval after administration before resuming nursing.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Allegro (fexofenadine) can interact with certain medicinal products and food substances, potentially altering its exposure in the body. These interactions primarily affect the absorption and systemic concentrations of fexofenadine.

Documented Interactions

Interacting Product Category	Specific Agents	Effect on Fexofenadine	Mechanism
Antacids	Aluminum- and magnesium-containing antacids	Decreases plasma concentration and absorption (AUC and Cmax)	Reduced gastrointestinal absorption/binding
Antibiotics/Antifungals	Erythromycin, Ketoconazole, and other azole antifungals	Increases plasma concentration (AUC and Cmax)	Enhanced gastrointestinal absorption; potential P-glycoprotein inhibition
Beverages	Grapefruit, Orange, and Apple Juices	Decreases bioavailability and systemic exposure	Inhibition of intestinal OATP transporters

Regulatory Timing and Constraints

To manage interactions that reduce absorption, fexofenadine should not be taken closely in time with antacids containing aluminum or magnesium. Regulatory guidelines suggest separating the administration of these antacids by at least 15 minutes (some sources suggest two hours or more) from the fexofenadine dose. Furthermore, fexofenadine should be taken with water and must not be consumed with fruit juices (grapefruit, apple, or orange) as these significantly reduce its effectiveness.

Population-Specific Notes

Patients with renal impairment (kidney disease) should use this medicine with caution. The effects of fexofenadine may be increased in this population because the drug is primarily eliminated by the kidneys, and decreased kidney function can lead to slower removal and prolonged elimination half-life.

Mechanism of Action

Ontology: How Allegro Works

Frovatriptan acts as a highly selective agonist at the 5 -HT1 B and 5 -HT1 D serotonin receptor subtypes, initiating an inhibitory cellular cascade through Gi/Go protein coupling. This molecular action directly modulates key neurovascular signaling dynamics within the trigeminovascular system.

The mechanism engages two complementary physiological actions: 5 -HT1 B activation induces vasoconstriction of dilated intracranial extracerebral vessels, and 5 -HT1 D activation inhibits the release of vasoactive neuropeptides (such as CGRP) from trigeminal nerve terminals. This dual modulation suppresses the activation of the trigeminovascular system.

Frovatriptan exhibits prolonged receptor occupancy, which translates to a highly sustained pharmacological influence over its 5 -HT1 B/1D targets. This enduring mechanistic engagement provides extended physiological modulation, influencing the resulting duration of pathway activity.

Dosage and Administration Information

How Allegro is Used

Allegro (frovatriptan) is an oral medication administered solely for the acute treatment of a migraine attack; it is not indicated for migraine prevention. The medicine is formulated as a 2.5 mg film-coated tablet and must be swallowed whole with fluids. Administration may occur without regard to meals, as food does not significantly affect the drug’s absorption profile.

Official Dosing and Timing Protocol

The standard regimen involves taking a single 2.5 mg dose as soon as possible after the onset of the migraine headache. If the headache returns after initial relief, a second 2.5 mg dose may be administered. A minimum interval of at least 2 hours must pass between the first and second dose. If the first dose fails to provide any response for a particular attack, a second dose should not be taken for that same headache.

Frequency and Limits

Strict limits are established on total use. The total dose generally should not exceed 7.5 mg (three tablets) within any 24-hour period; however, a maximum dose of 5 mg (two tablets) per 24 hours is also specified in certain clinical contexts. The safety of treating more than four migraine attacks in a 30-day period has not been established, and use on ten or more days per month is associated with the risk of developing Medication Overuse Headache (MOH).

Population Considerations

Dose adjustment is generally not required for patients with renal impairment or mild-to-moderate hepatic impairment. Use is typically not recommended in pediatric patients (under 18) and older adults (over 65) due to limited clinical experience and established safety data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allegro (Frovatriptan)

Evidence for the Acute Treatment of Migraine Attacks

The core evidence base for Allegro's studied indication includes short-term, placebo-controlled Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in research exploring how symptoms change over time when an acute migraine attack is underway. The populations studied were typically adults experiencing episodic migraine, where research examined the immediate response to treatment.

Primary outcomes measured in these trials included the percentage of participants who achieved headache relief or were assessed for pain-free status at short, defined intervals, usually two hours after taking the medication. Secondary outcomes measured included outcomes reflecting daily functioning or activity level and the resolution of common associated symptoms, such as nausea and sensitivity to light or sound.

Research on Sustained Relief and Recurrence

Research on Allegro has explored its pharmacokinetic characteristics in relation to the potential for sustained relief. These research scenarios monitored how long the initial relief lasted and the rate at which the headache returned, known as headache recurrence, within a timeframe of 24 to 48 hours post-dose. This research specifically examined temporary physiological imbalance related to migraine.

Studies monitored outcomes reflecting daily functioning or activity level, tracking participants to see if sustained pain freedom was observed, meaning the pain did not return or require a second dose of medication. Findings describe patterns related to the measured recurrence rate in studies where Allegro was observed over defined time intervals, providing context into research exploring short-term symptom changes during the period of heightened symptom activity.

What is Still Uncertain in the Research Landscape

Comparative evidence is lacking for direct, head-to-head comparisons against every newer triptan medication. Furthermore, long-term outcomes are not fully established, as the core trials were designed for immediate results. Data for certain groups, such as older adults, remain limited, and subgroup findings are uncertain for these populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Allegro (FAQ)

Q: Is Allegro the same as fexofenadine?

Allegro tablets contain Frovatriptan, a triptan medication specifically used for migraine headaches. Fexofenadine, the active ingredient in a medicine commonly known as Allegra, is used to treat allergies. Official documents clarify that the drugs belong to different pharmacological classes and address separate conditions.

Q: Why is Allegro sometimes called a non-drowsy allergy medicine?

The medicine known as Allegro (frovatriptan) is officially approved for the acute treatment of migraine attacks. This name confusion arises because an unrelated allergy medicine contains fexofenadine, which is often marketed as a non-drowsy product.

Q: What kind of allergies is Allegro typically used for?

According to official product information, Allegro (frovatriptan) is indicated only for the acute treatment of migraine attacks in adults. Official product information confirms that it is not approved for the treatment of any allergic conditions.

Q: How quickly does Allegro usually start to work?

Studies indicate that the active ingredient reaches its highest concentration in the bloodstream approximately 2 to 4 hours after a single oral dose. Trials generally assess the percentage of people who achieve a headache response at the two-hour mark following administration.

Q: Is Allegro available without a prescription in some places?

Official regulatory information classifies Allegro (frovatriptan) as a prescription medication. The drug's classification as a triptan is consistent with it being listed as a prescription medication in regulatory documents.

Q: Is a headache a reported side effect of Allegro?

Yes, regulatory documents indicate that headache is listed as an adverse reaction based on clinical trial data. It is a documented effect of the drug's use.

Q: Does Allegro interact with common cold or flu medications?

Official documents list known interactions with certain drug classes, such as other triptans, ergotamines, and medications that may increase serotonin levels. The official label does not explicitly mention general over-the-counter cold or flu preparations.

Q: What happens if a dose of Allegro is missed?

Allegro is an acute treatment to be taken only when a migraine attack has started. Given this, the concept of a regularly scheduled or 'missed dose,' as is the case for maintenance medications, does not apply to its protocol.

Q: Is there a different name for Allegro in other countries?

The active ingredient in Allegro is Frovatriptan. While 'Allegro' is a specific trade name in some regions, the medicine may be marketed under a different brand name or as generic Frovatriptan in other countries.

Q: Do research studies support the use of Allegro for hay fever?

No. Official research and regulatory evidence are based on randomized, controlled trials supporting the drug’s effectiveness for the acute treatment of migraine attacks. There is no regulatory basis or evidence supporting its use for hay fever.

Q: Has Allegro been studied for treating chronic hives?

No. The regulatory indication for Allegro (frovatriptan) is strictly limited to the acute treatment of migraine attacks in adults. The official evidence base does not include studies related to chronic hives or other dermatological conditions.

Q: What is the difference between prescription Allegro and over-the-counter Allegro products?

The official product containing Frovatriptan is defined in regulatory documents as a prescription-only medication. The prescribing information does not list or describe an over-the-counter version of the frovatriptan product.

Q: What is considered an overdose of Allegro?

The maximum recommended daily dosage is strictly defined in the product label. In the event of an overdose, regulatory documents recommend seeking immediate medical attention. Symptoms observed in clinical trials at high doses included dizziness and lack of coordination.

Q: Why might a doctor prescribe Allegro instead of another antihistamine?

A doctor would prescribe Allegro (frovatriptan) because it is a triptan, a class of medicine specifically intended to address the underlying neurovascular changes of an acute migraine attack. Antihistamines, by contrast, are used to treat allergic conditions.

Q: Can Allegro be taken with alcohol?

Official product information indicates that consuming alcohol with this medication may be associated with central nervous system side effects. These effects may include dizziness or fainting spells.

Q: What is the purpose of Allegro's extended-release formulation?

Allegro is manufactured as a film-coated tablet and is not classified as an extended-release formulation in regulatory documents. It is characterized by the longest half-life (approximately 26 hours) among the triptan class, which helps provide sustained pharmacological action.

Q: Do studies show Allegro is effective for indoor dust allergies?

No. Official regulatory documents indicate that Allegro is only intended for the acute treatment of migraine headaches in adults. It has not been studied or approved for use against indoor dust allergies.

Q: Can Allegro lose its effectiveness over time (tolerance)?

The regulatory label cautions against taking the drug for ten or more days per month. Frequent use is associated with the risk of developing a Medication Overuse Headache (MOH), as described in official documents.

Q: Are there any contraindications related to eye conditions for Allegro?

The regulatory documents do not list general eye conditions as contraindications. Allegro is contraindicated for specific types of migraine, and the label notes that the drug is not indicated for rare headaches such as ophthalmoplegic migraine.

Q: Does Allegro have any known interactions with herbal supplements?

Official interaction information does not specifically list common herbal supplements. Caution is generally advised with any product that may affect serotonin levels due to the potential risk of Serotonin Syndrome.

Q: What are the symptoms of an allergic reaction to Allegro itself?

Official warnings for potential hypersensitivity reactions (allergic reactions) may include difficulty breathing, hives, swelling of the face, lips, mouth, or tongue, and skin rash.

Q: Is Allegro effective for pet allergies?

No. Allegro is a prescription medicine indicated only for the acute treatment of migraine attacks. The official regulatory documents do not include information on its use or effectiveness for pet allergies.

Q: Can Allegro be taken together with vitamins?

Regulatory interaction information details issues with specific drugs, antacids, and certain fruit juices that can affect absorption. General vitamin supplements are not explicitly listed as interacting, but the label does caution against consuming grapefruit, orange, and apple juices, which can reduce the drug's effectiveness.

Q: Is Allegro safe to take with certain pain relievers, according to product information?

Regulatory documents advise against taking Allegro within 24 hours of other triptans or ergotamine-containing medications. The label does not specifically contraindicate common, non-serotonergic pain relievers, such as those containing ibuprofen or acetaminophen.

Q: What should I do if I think I'm experiencing a rare side effect of Allegro?

Official regulatory guidance describes situations where immediate medical attention may be needed for symptoms suggestive of a serious event, such as heart problems or stroke. Patients are also advised in official documents to report all adverse reactions to their healthcare provider.

How should Allegro be stored and disposed of?

The storage and disposal of Allegro (frovatriptan) tablets must follow strict regulatory guidelines to ensure stability and public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) [1.1].
Protection	Keep from freezing and protect from excessive moisture and direct light [1.1, 1.2].
Child Safety	Keep out of the sight and reach of children [1.1].

Disposal Instructions

Official disposal guidance recommends two options for unused or expired tablets:

The primary method is to use a drug take-back location or mail-back program [1.7, 1.8].
Alternatively, the medicine may be mixed with an undesirable substance (e.g., dirt, cat litter) in a sealed bag and thrown into the household trash [1.5, 1.7].

Allegro is not on the FDA's list of medicines recommended for flushing; therefore, it should not be disposed of in the toilet or sink [1.9].

Allegro